Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years
| العنوان: | Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 10 Outpatient Diabetes Clinics in Sweden over 5 Years |
|---|---|
| المؤلفون: | Matuleviciene, Aldina Pivodic, Mark A. Clements, Sofia Dahlqvist, Martin Fahlén, Börje Haraldsson, Stig Attvall, Marcus Lind, Magnus Ekelund |
| المصدر: | Diabetes Technology & Therapeutics. 17:21-28 |
| بيانات النشر: | Mary Ann Liebert Inc, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, Insulin pump, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Ambulatory Care Facilities, Body Mass Index, Insulin Infusion Systems, Endocrinology, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Retrospective Studies, Glycemic, Glycated Hemoglobin, Sweden, Type 1 diabetes, business.industry, nutritional and metabolic diseases, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Clinical Practice, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Treatment Outcome, Hyperglycemia, Female, business, Body mass index |
| الوصف: | Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may also exist.We used data from 10 outpatient diabetic clinics in Sweden and studied CSII treatment over 5 years. Patients with HbA1c values available ≤ 6 months before starting CSII and at 5 years were included (n = 272, 82% of CSII patients) along with 2,437 contemporaneous controls on multiple daily insulin injections (MDI). Baseline variables evaluated were age, sex, diabetes duration, insulin dose, body mass index (BMI), HbA1c at baseline, and outpatient clinical care unit.At 5 years, significantly greater reductions in HbA1c by CSII compared with MDI were found for patients with higher baseline HbA1c (P = 0.032) and lower baseline BMI (P = 0.013). For baseline HbA1c levels of 7.0%, 8.0%, and 9.0% and a BMI of 25 kg/m(2), the reduction in HbA1c level by CSII was 0.08% (difference not significant), 0.16% (95% confidence interval, 0.03-0.29%), and 0.25% (95% confidence interval, 0.11-0.39%), respectively. Corresponding analyses for the change in HbA1c level from start to 1 and 2 years revealed a significant interaction of insulin pump therapy only with baseline HbA1c levels (P0.001 and P = 0.030, respectively). The interaction term between outpatient clinical care unit and CSII treatment was statistically significant for some care units, with some care units demonstrating a benefit from CSII and others demonstrating a detriment.Patients with high HbA1c levels have a greater probability of improved HbA1c after initiating pump therapy, but effects remain relatively modest even for patients with poor control. Factors predicting successful insulin pump use need further study. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f88186c0afc29c165924bfcda791c26bTest https://doi.org/10.1089/dia.2014.0139Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....f88186c0afc29c165924bfcda791c26b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|